By: IPP Bureau
Last updated : May 21, 2025 11:50 am
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Marksans Pharma reported the financial results for the quarter and year ended March 31, 2025.
During Q4 FY25, Operating Revenue stood at Rs. 708.5 crore, up by 26.5% YoY driven growth across key markets, led by US region. Gross profit stood at Rs. 383.2 crore, up by 32.1% YoY, with a gross margin expansion of 228 bps YoY to 54.1%. Growth is attributed to softening of raw material prices and a better product mix. EBITDA stood at Rs. 125.8 crore. up by 14.7% YoY, with a margin of 17.8%. PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24.
For FY25, Operating Revenue stood at Rs. 2,622.8 crore, up by 20.5% YoY driven by growth across all markets. Gross profit came in at Rs. 1,479.1 crore, up by 29.8% YoY, with a gross margin of 56.4%. ▪ EBITDA stood at Rs. 528.6 crore, up by 15.3%, with an EBITDA margin of 20.2%. PAT stood at Rs. 382.6 crore as compared to Rs. 314.9 crore, reflecting a growth of 21.5%.
Mark Saldanha, Managing Director of the Company said “We are pleased to announce another year of robust performance; we have achieved highest ever annual revenues and profits. In FY25, we witnessed strong performance across all our markets, the US market has been a key growth driver with 35% YoY increase in revenue. Our OTC segment’s performance is at all-time high, crossing INR 2000 Crs in revenue, a testament to our focus and execution on expanding the OTC product pipeline. Looking forward, we continue to strengthen our foundation by increasing the capacity and strengthening our product pipeline. We are optimistic about building on this momentum and create morevalue for our stakeholders in the coming years.”